ABSTRACT
Funding access to medical innovations, including pharmaceuticals and others medical technologies, is becoming increasingly challenging (Morgan et al. 2013). This is a situation that is not expected to ease in the near future. On the contrary, recent nancial disturbances in the global economy are straining governments’ budgets still more. Health care systems and their administrators, already under strict budget constraints, will very likely continue to face difcult decisions with regard to budget allocation. The prioritization of technologies for investment is one of the difcult choices confronting health care decision makers.
